Literature DB >> 18660862

Concomitant medications and possible side effects of antimuscarinic agents.

Scott A Macdiarmid1.   

Abstract

Antimuscarinic agents are the treatment of choice for overactive bladder syndrome; clinical experience and the literature support their efficacy, tolerability, and safety. The most common side effects experienced include dry mouth and constipation. Many commonly prescribed drugs have anticholinergic effects that could increase the anticholinergic "load" or "burden" in patients with overactive bladder, potentially increasing the frequency and severity of side effects. In addition, the adverse events associated with antimuscarinics may be more pronounced in the elderly, especially those taking multiple medications. Knowledge regarding the potential side effects associated with antimuscarinics is important so that patients can be advised and effectively treated.

Entities:  

Keywords:  Antimuscarinic agents; Darifenacin; Elderly; Overactive bladder; Oxybutynin; Side effects; Solifenacin; Tolterodine; Trospium chloride

Year:  2008        PMID： 18660862      PMCID： PMC2483325     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  20 in total

1.  Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.

Authors:  F Haab; L Cardozo; C Chapple; A M Ridder
Journal:  Eur Urol       Date:  2005-01-05       Impact factor: 20.096

2.  A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.

Authors:  C R Chapple; R Martinez-Garcia; L Selvaggi; P Toozs-Hobson; W Warnack; T Drogendijk; D M Wright; J Bolodeoku
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

3.  Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist.

Authors:  Jenelle Foote; Karin Glavind; Georg Kralidis; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

4.  Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Authors:  P Van Kerrebroeck; K Kreder; U Jonas; N Zinner; A Wein
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

5.  Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies.

Authors:  Scott A MacDiarmid; Rodney U Anderson; Robert B Armstrong; Roger R Dmochowski
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

6.  A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.

Authors:  Christopher Chapple; William Steers; Peggy Norton; Richard Millard; Georg Kralidis; Karin Glavind; Paul Abrams
Journal:  BJU Int       Date:  2005-05       Impact factor: 5.588

7.  An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.

Authors:  William Steers; Jacques Corcos; Jenelle Foote; Georg Kralidis
Journal:  BJU Int       Date:  2005-03       Impact factor: 5.588

8.  Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.

Authors:  Roger R Dmochowski; Peter K Sand; Norman R Zinner; David R Staskin
Journal:  Urology       Date:  2008-03       Impact factor: 2.649

9.  Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

Authors:  C R Chapple; T Rechberger; S Al-Shukri; P Meffan; K Everaert; M Huang; A Ridder
Journal:  BJU Int       Date:  2004-02       Impact factor: 5.588

10.  Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.

Authors:  David Staskin; Peter Sand; Norman Zinner; Roger Dmochowski
Journal:  J Urol       Date:  2007-07-16       Impact factor: 7.450
View more
  5 in total

Review 1.  Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.

Authors:  Michael G Oefelein
Journal:  Drug Saf       Date:  2011-09-01       Impact factor: 5.606

2.  Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns Analyzer.

Authors:  Daniel B Ng; Melissa McCart; Christopher Klein; Chelsey Campbell; Robert Schoenhaus; Todd Berner
Journal:  Am Health Drug Benefits       Date:  2016-09

Review 3.  Vulnerable elderly patients and overactive bladder syndrome.

Authors:  Stephen R Kraus; Tamara Bavendam; Tiffany Brake; Tomas L Griebling
Journal:  Drugs Aging       Date:  2010-09-01       Impact factor: 3.923

4.  Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up.

Authors:  Roberto Angioli; Roberto Montera; Francesco Plotti; Alessia Aloisi; Eva Montone; Marzio Angelo Zullo
Journal:  Int Urogynecol J       Date:  2012-09-08       Impact factor: 2.894

5.  A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.

Authors:  Revanna Manjunatha; Hulikallu Purushotama Pundarikaksha; Basavanahalli Krishnaiah Hanumantharaju; Satenahalli Javaregowda Anusha
Journal:  J Clin Diagn Res       Date:  2015-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.